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Transcriptional regulation via activator protein-1 (AP-1) protein binding to AP-1 binding sites within gene promoter
regions of AP-1 target genes plays a key role in controlling cellular invasion, proliferation, and oncogenesis, and is
important to pathogenesis of arthritis and cardiovascular disease. To identify new proteins that interact with the AP-1
DNA binding site, we performed the DNA affinity chromatography-based Nucleotide Affinity Preincubation Specificity
TEst of Recognition (NAPSTER) assay, and discovered a 97 kDa protein that binds in vitro to a minimal AP-1 DNA
sequence element. Mass spectrometric fragmentation sequencing determined that p97 is nucleolin. Immunoblotting
of DNA affinity-purified material with anti-nucleolin antibodies confirmed this identification. Nucleolin also binds
the AP-1 site in gel shift assays. Nucleolin interacts in NAPSTER with the AP-1 site within the promoter sequence of the
metalloproteinase-13 gene (MMP-13), and binds in vivo in chromatin immunoprecipitation assays in the vicinity of the
AP-1 site in the MMP-13 promoter. Overexpression of nucleolin in human HeLa cervical carcinoma cells significantly
represses AP-1 dependent gene transactivation of a minimal AP-1 reporter construct and of an MMP-13 promoter
reporter sequence. This is the first report of nucleolin binding and transregulation at the AP-1 site.  2007 Wiley-Liss, Inc.
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INTRODUCTION
The activator protein-1 (AP-1) transcription factor
is involved in coordinate regulation of gene expres-
sion events that control diverse cellular processes,
including cellular invasion, cell cycle regulation, cell
differentiation, tissue remodeling, DNA repair, apop-
tosis, oncogenesis, and metastasis [1–4]. AP-1 is a key
mediator in the pathogenesis of cancer, arthritis,
cardiovascular, and other disease states [2,4–10]. AP-
1 binds and regulates numerous genes containing
TGAc/gTCA consensus cis regulatory elements (call-
ed AP-1 DNA binding sites or AP-1 sites), which
generally lie within gene promoter regions [11,12].
Proteins encoded by jun family and fos family proto-
oncogenes compose the AP-1 dimer as Jun-Jun
homodimers or as Jun-Fos heterodimers. The jun
family consists of c-jun, junB, and junD, and the fos
family consists of c-fos, fra-1, fra-2, and fosB. Many
genes harboring AP-1 sites are transcriptionally
activated in response to endogenous and extracel-
lular stimuli, including hormones, growth factors,
oncogenes, tumor promoters such as 12-O-tetrade-
canoyl phorbol-13-acetate (TPA), and many other
carcinogenic agents [3]. Matrix metalloproteinases
(MMPs) and genes in many other functional classes
are regulated by AP-1 and implement physiological
responses elicited by these agents [10]. MMPs play
important roles in the degradation of extracellular
matrix (ECM) molecules during wound healing,
tissue remodeling, and angiogenesis, and in patho-
logical processes including tumor invasion, metas-
tasis, and arthritis [13,14].
MOLECULAR CARCINOGENESIS 47:34–46 (2008)
 2007 WILEY-LISS, INC.
Abbreviations: AP-1, activator protein-1; TPA, 12-O-tetradecanoyl
phorbol-13-acetate; ECM, extracellular matrix; NCL, nucleolin;
NAPSTER, Nucleotide Affinity Preincubation Specificity TEst of
Recognition; MMP-13, matrix metalloproteinase-13; HA, hemaglu-
tinin; Topo, topoisomerase-1; GAPDH, glyceraldehydes phosphate
dehydrogenase; CMV, cytomegalovirus; b-gal, beta galactosidase;
GALV, gibbon ape leukemia virus; NE, nuclear extract; ChIP,
chromatin immunoprecipitation; PCR, polymerase chain reaction;
bp, base pair; DMSO, dimethyl sulfoxide; YB-1, Y-box binding
protein-1.
Shaija Samuel and Jean-Claude Twizere contributed equally to
this study.
Shaija Samuel’s present address is Department of Cancer Biology,
University of Texas M.D. Anderson Cancer Center, 1515 Holcombe
Boulevard, Box 184, Houston, TX 77030.
Jean-Claude Twizere’s present address is Biologie cellulaire et
mole´culaire, Faculte´ Universitaire des Sciences Agronomiques,
Gembloux, Belgium.
*Correspondence to: 248 Reynolds Medical Building, Texas, A &
M College of Medicine, College Station, Texas 77843-1114.
Received 19 January 2007; Revised 26 April 2007; Accepted 27
April 2007
DOI 10.1002/mc.20358
Nucleolin (NCL) is an abundant and ubiquitous
protein (see Reference [15] for review). NCL binds to
several distinct nucleotide sequences in RNA and
DNA [16,17]. NCL is a major component of the
nucleolus, and is also present in the nucleoplasm and
cytoplasm [16]. NCL has been implicated in numer-
ous functions, including chromatin condensation
and remodeling, processing and stabilization of
RNA, and activation and repression of transcription
[15–23].
The Nucleotide Affinity Preincubation Specificity
TEst of Recognition (NAPSTER) microscale DNA
affinity chromatography-based binding assay was
devised to identify new sequence-specific DNA
binding proteins [24,25]. Using NAPSTER, we pre-
viously identified a 97 kDa protein that binds to a
consensus AP-1 DNA sequence [26]. We now report
that p97 is nucleolin. Nucleolin binds in vitro and in
vivo to the promoter sequence of the matrix
metalloproteinase-13 (MMP-13) gene, in the vicinity
of the AP-1 site. Overexpression of nucleolin
represses transactivation from a minimal AP-1




Reagents and supplies not described here were
purchased from vendors cited [25,29].
Antibodies
Anti JunD antibodies (aJunD; [29]), rabbit anti
NCL antibody (aNCL; Catalog #sc-8031), ahemaglu-
tinin (aHA; Cat. #sc-805), and aTopoisomerase I
(Cat. #sc-10783), were from Santa Cruz Biotechnol-
ogy (Santa Cruz, CA). A second rabbit aNCL antibody
was from Medical Biological Laboratories Co. Ltd.
(MBL, Nagoya, Japan; Cat. #M019-3). aGlyceralde-
hyde phosphate dehydrogenase (GAPDH) was a
mouse monoclonal from Research Diagnostics, Inc.
(Flanders, NJ; Cat. #RDI-TRK5G4-6C05). Rabbit non-
immune IgG was from Active Motif (Carlsbad, CA).
Peroxidase conjugated anit-rabbit and anti-mouse
secondary antibodies were from Calbiochem (San
Diego, CA).
Immunoblotting Analyses
Western immunoblotting was performed as
described [25,26,29]. Immunoblotting with aNCL
and with aJunD were performed at an antibody
concentration of 0.5 mg/ml. aTopoisomerase I and
aHA-tag were used at 0.2 mg/ml. aGAPDH was used at
0.4 ng/ml.
Plasmids
pcDNA3.1(þ) was from Invitrogen (Carlsbad, CA).
HA-tagged full length NCL expression construct
pNtag4 under the control of the constitutive cyto-
megalovirus (CMV) promoter was a gift of Dr. N.
Maizels (U. Washington). pSVbgal plasmid harbor-
ing a full length beta galactosidase (b-gal) gene was
from Promega (Madison, WI). The CMV expression
construct pcDNAc-Fos, which harbors a full length
human c-fos gene insert, was a gift of Dr. N. Colburn
(NCI-FCRDC, Frederick, MD). Wild-type (wt) and
mutant (mut) AP-1 luciferase constructs harboring
three tandem copies of the wt AP-1 sites (50-agcca
gagaaatagatgagtcaacagc-30, AP-1 sequence under-
lined) or mut AP-1 sites (50 agccagagaaatagaggagtc-
tacagc-30, AP-1 sequence underlined, mutations in
bold) from the gibbon ape leukemia virus long
terminal repeat (GALV-LTR) were constructed as
described [25]. MMP-13 promoter reporter con-
structs containing wt and mut AP-1 sites were a gift
of Dr. C. Brinckerhoff (Dartmouth College; [30]).
Cell Culture
Human HT29 adenocarcinoma cells and human
HeLa cervical carcinoma cells were grown as
described [25].
Nuclear Extract Preparation
Nuclear extracts (‘‘NE’’) from human HT29 cells
and HeLa cells treated with TPA were made as
described [24–26,29]. NE from human MCF-7 breast
cancer cells was purchased from Active Motif.
NAPSTER AP-1 DNA Binding Assays
NAPSTER assays were performed with streptavidin
beads coupled to double-stranded AP-1 oligos as
described [26]. Beads attached to the wt GALV oligo
harbored a 27bp 1X GALV sequence, the same as that
which is inserted into the GALV luc reporter
constructs. Other assays employed a sequence from
the human MMP-13 promoter, 50-CCTATCCA-
TAAGTGATGACTCACCATT-30.
NAPSTER employed three samples in which NE
was subjected to batchwise chromatography with
GALV or MMP-13 DNA beads. Sample I, direct
mixing of AP-1 DNA beads with NE; samples II and
III, AP-1 DNA mixing of beads with NE after pre-
incubation with 2.5-fold molar excess of wt or
mutant (mut) AP-1 DNA oligo in solution, respec-
tively. Mutated GALV and MMP-13 oligos harbored
two mutations in the AP-1 site: 50-GGAGTCT-30,
mutations in bold.
Purification of p97
1.8 mg HT29 NE was dialyzed against buffer Z and
subjected to batchwise affinity chromatography by
pre-clearing with 120 mg of mut AP-1 DNA conju-
gated to wt GALV AP-1 NAPSTER beads in the
presence of 3.6 mg/ml polydI/dC. Samples were
incubated for 60 min on a rotating clip wheel at
48C, and centrifuged for 60 s at 9500g. Mut beads
were discarded. Supernatant samples were divided
into three equal samples I, II, and III, containing
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600 mg each of NE protein. Samples II and III were
subjected to pre-incubation with 50 mg of wt (sample
II) or mut (sample III) unconjugated GALV AP-1
oligos followed by DNA affinity chromatography
with wt AP-1 DNA beads containing 20 mg of wt AP-1
DNA. Samples were incubated and washed as
described for NAPSTER analyses [24].
Pellets for samples I, II, and III were subjected to
SDS–PAGE [26,29]. Samples were electrophoresed
overnight at 5 mA in a minigel apparatus (BioRad
Laboratories, Hercules, CA), such that the 30 kDa
molecular weight marker reached the bottom of
the gel. The gel was stained with Coomassie
brilliant blue. Gel bands corresponding to purified
97 kDa protein species in samples I and III, and to
that Rf position in sample II (which lacked
stainable quantities of p97 protein), representing
about 200–400 fmol of protein, were excised for
further analyses.
Mass Spectrometric Mass Spectrometry
Fragmentation Sequencing Analysis of p97
Gel bands were submitted for mass spectrometric
mass spectrometry fragmentation sequencing ana-
lyses (‘‘MS/MS sequencing’’) at the Yale HHMI
Biopolymer Laboratory/W.M. Keck Foundation Bio-
technology Resource Laboratory (http://info.med.
yale.edu/wmkeck/prochem). Proteins were trypsi-
nized for 18 h, eluted, and analyzed by MS/MS.
Liquid LC-MS/MS chromatography was used for
sample I of p97 and nanospray MS/MS was used for
samples II and III. All spectra were searched manually
and by using the Mascot peptide mass fingerprint
algorithm for protein identification (http://www.
matrix-science.com/search_form_select.html).
Gel Shift Assays
Electrophoretic mobility shift assays (gel shift
assays were performed with NE from human MCF-7
breast cancer cells as described [29].
Transactivation Assays
2 105 adherent HeLa cells were plated onto 6 well
35 mm dishes. Twelve hours after plating, luciferase
reporter constructs harboring wt or mut AP-1 sites
were transiently co-transfected with 1 mg pNtag4,
HA-tagged NCL CMV expression construct, and
600 ng of pSVbgal expression vector, as described
[25]. Cells that received no transfected pNtag4 were
transfected with 1 mg pcDNA3.1(þ) control vector
(InVitrogen). Ten nanograms of c-fos expression
construct was transfected in some experiments. Cells
were harvested at 24 h post-transfection and assayed
for luciferase and b-gal activities [25].
Chromatin Immunoprecipitation Assays
HeLa cells were treated for 24 h with 100 ng/ml
TPA. Chromatin was prepared and assayed in
chromatin immunoprecipitation (ChIP) assays using
a ChIP-IT kit (Active Motif) according to the kit
protocol. Five microgram chromatin samples were
used for each immunoselection. Chromatin was pre-
cleared with 100 ml of Protein G beads for 90 min,
immunoselected, and processed as described in the
protocol. It was then subjected to polymerase chain
reaction (PCR) amplification with 1 unit of Platinum
Taq polymerase per reaction (Invitrogen), using the
primers indicated in Table 1. Polyacrylamide gel
electrophoresis of PCR products in Tris-borate EDTA
buffer was performed in 10% native PAGE gels
with half of the reaction mix. Gels were visualized
with a FluorChem 8900 imaging system (Alpha
Innotech, San Leandro, CA) after staining for 5 min
in 1 mg/ml ethidium bromide in water.
RESULTS
p97, a New Protein That Binds the AP-1 DNA Binding Site
NAPSTER is an analytical DNA affinity chromato-
graphy-based method used to identify new sequence-
specific DNA binding proteins in a rapid microscale
assay. In the NAPSTER assay, nuclear extracts (NE)
either directly undergo AP-1 DNA affinity chromato-
graphy (Sample ‘‘I’’ in all NAPSTER experiments) or
are first preincubated with excess soluble wt oligo
(Sample ‘‘II’’) or mutated AP-1 oligo (Sample ‘‘III’’)
prior to chromatography. Mutated AP-1 sequences
contain mutations that have been shown in previous
studies to abrogate DNA binding and transactivation
by AP-1 proteins [12,24,26,29]. Batchwise microscale
DNA affinity chromatography is then performed, by
means adapted from Lee et al., with numerous
modifications [11,24,26]. Samples from NAPSTER
isolation are then subjected to SDS–PAGE and
Western immunoblotting with antibodies against
the proteins of interest. Using NE from human HT29
cells, we observe specific binding of all seven
Jun and Fos AP-1 subunits to the AP-1 DNA
binding site [25].
In previously published studies, we had identified
a 97 kDa protein that binds specifically to the AP-1
DNA binding site in NAPSTER [26]. In the current
work described herein we purified p97 protein from
crude HT29 nuclear extracts so that it could be
identified by mass spectrometric mass spectrometry
fragmentation sequencing analyses (‘‘MS/MS
sequencing’’).
p97 protein was purified by a three-step protocol
from HT29 NE in which NE was pre-cleared with AP-1
DNA affinity beads containing a mutated AP-1 site,
followed by NAPSTER purification with wt AP-1 DNA
affinity beads, and SDS–PAGE. As shown in the
Coomassie-stained gel in Figure 1, NAPSTER samples
I and III but not sample II reproducibly contain p97
protein. A band of approximately 120 kDa also
exhibited partially specific binding, but this was
not consistently detected. p97 protein bands from
samples I and III, and a gel slice at the corresponding
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Rf position from sample II, were excised and
subjected to in-gel tryptic digestion followed by
MS/MS sequencing. Since samples I and III contain
p97 whereas sample II lacks p97, we predicted that
proteins of the same identities would be found in
samples I and III but would be lacking in sample II.
Sixteen of the nineteen peptides generated from
sample I matched to the protein nucleolin (Table 1).
A single peptide in sample I matched to topoisome-
rase I. Sample I was thus designated as nucleolin
(‘‘NCL’’). Sample II contained only a small amount of
Coomassie-stained protein. Of the eight peptides





match Protein ID Sequence Comments
Sample I
1323.63 Yes Nucleolin EAoxMEDGEIDGNK
995.53 Yes Nucleolin NSTWSGESK
1307.63 No Yes Nucleolin EAMEDGEIDGNK
1322.77 Yes Nucleolin GLSEDTTEETLK
1000.63 Yes Nucleolin NDLAVVDVR
1178.69 Yes Nucleolin EVFEDAAEIR
1160.69 Yes Nucleolin SISLYYTGEK
937.49 Yes Nucleolin TGISDVFAK
1112.65 Yes Topo I AEEVATFFAK
2200.26 Yes Nucleolin GLSEDTTEETLKESFDGSVR
940.61 No Yes Nucleolin GIAYIEFK
1755.11 No Poor ion fragmentation
1510.85 No Yes Nucleolin SATEET[IL][QK]EVFEK
1777.05 No Yes Nucleolin KFGYVDFESAEDLEK
1648.89 Yes Nucleolin FGYVDFESAEDLEK
1561.85 Yes Nucleolin GFGFVDFNSEEDAK
1594.91 Yes Nucleolin GYAFIEFASFEDAK
1761.03 No Yes Nucleolin SYSATEETLQEVFEK
2211.36 Yes Trypsin Enzyme used for digestion
Sample II
1189.73 No No DND[IL]M[IL]VR No match in database
1408.79 No Yes DNAliga-
seIII
AAVWEITGAEFSK Top Mascot and manual match
1420.79 No No T[QK][QK][IL] Unable to make reasonable match
1383.79 No No Y[QK]EGA Too short for meaningful match
1020.59 No No Insufficient fragmentation
1127.59 No No Insufficient fragmentation
1023.53 No No Very complex spectra
1175.71 No No [FoxM]ED Too short for search
Sample III
1160.71 No Yes Nucleolin SISLYYTGEK
1178.69 Yes Nucleolin EVFEDAAEIR
1322.77 Yes Nucleolin GLSEDTTEETLK
1510.85 No Yes Nucleolin TEET[IL][QK]EV Sequence tag matches nucleolin
1648.93 Yes Nucleolin FGYVDFESAEDLEK
1754.11 No Yes Topo I GPVFAPPYEPLPENVK
1561.67 Yes Nucleolin GFGFVDFNSEEDAK
937.59 No Yes Nucleolin TGISDVFAK
1420.89 No No Unable to call reasonable sequence
1594.91 Yes Nucleolin GYAFIEFASFEDAK
1201.67 No Yes keratin Probable contaminant of sample
1425.83 No No No sequence could be called
1000.65 Yes Nucleolin NDLAVVDVR
MS/MS data for samples I, II, and III isolated from Coomassie stained bands run in SDS–PAGE gels (Fig. 1) are shown. Measured molecular
weights (‘‘MþH’’) of all peptide fragments are shown in Column 1. Identification of matches in the Mascot Peptide mass fingerprint
algorithm are designated in Column 2 (‘‘Mascot Match’’). When Mascot Matches were not obtained, manual matches were sought by
determining amino acid sequence based upon the difference in masses, and then performing protein Blast homology searches to identify
protein matches. Protein identities (‘‘Protein ID’’) are designated in Column 4, and peptide sequences are designated in column 5. In
column 5, row 1, ‘‘oxM’’ designates oxidized methionine. Bracketed amino acids in Column 5 (e.g., [IL]) indicate ambiguous assignments
of amino acid identity (in this case residue assignment is either to I or L). Comments in column 6 indicate additional information about
data obtained.
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isolated and analyzed from sample II, no matches to
NCL were found. Seven peptides were present in
quantities insufficient to determine their identities,
and a single peptide matched to DNA ligase III. Since
two peptide matches to the same protein are
required to designate a sample as a given protein,
no protein designation was made for sample II. For
sample III, 9 of the 13 isolated peptides matched to
nucleolin either by Mascot or manual inspection.
One of the remaining four peptides matched
DNA topoisomerase I, one matched to keratin, and
two peptides had no matches. Sample III, like sample
I, was thus designated as NCL. Based on these
collective data we identified p97 as nucleolin.
Nucleolin Binds the AP-1 DNA Sequence in NAPSTER
Assays as Detected by Immunoblotting With Anti
Nucleolin Antibodies
Immunoblotting of NAPSTER samples from HT29
nuclear extracts with anti nucleolin (aNCL) anti-
bodies was performed to confirm that nucleolin
binds specifically to the AP-1 DNA sequence. As
shown in Figure 2A (left panel), samples I and III
contain a 97 kDa species that is recognized by aNCL,
whereas sample II does not. A second independently
generated aNCL antibody also recognizes the 97 kDa
band in NAPSTER samples I and III (not shown).
These data confirm that p97 is NCL. As expected, AP-
1 proteins encoded by the jun family of proto-
oncogenes also bind the AP-1 site in NAPSTER
(Fig. 2A, JunD middle panel, and data not shown).
NAPSTER with an antibody against topoisomerase I
(TopoI), for which a single peptide match was found
in each of samples I and III, shows TopoI binding to
the DNA, but its binding is not specific, since it is not
competed by preincubation with excess wt or mut
AP-1 oligo (Fig. 2A, right panel). Specific binding of
NCL to the AP-1 site is also observed using NE from
human HeLa cervical carcinoma cells, the latter of
which is a readily transfectable cell line amenable to
gene expression studies (Fig. 2B). Binding of NCL to
the AP-1 site using NE from HT29 and HeLa cells was
observed in 47 independent NAPSTER assays. Muta-
tion of the GALV AP-1 oligo abrogates specific
binding of NCL and AP-1 when the core 7 bp AP-1
sequence is mutated, but not when sequences along
the length of the flanking regions are mutated (not
shown). NCL and AP-1 also bind AP-1 oligos from the
MMP-13 promoter, which contains flanking
sequences different from the GALV AP-1 oligos (Fig.
5A and data not shown). Taken together, these data
indicate a requirement for the core AP-1 site but not
flanking sequences for NCL and AP-1 protein bind-
ing to the GALV AP-1 oligo.
NCL has previously been reported to bind to
single-stranded DNA [31,32]. To rule out the possi-
bility that NCL is binding to single-stranded DNA
that may be attached to the beads in contaminating
quantities, we prepared double-stranded AP-1 DNA
by annealing the biotinylated DNA strand with a
fivefold molar excess of the complementary strand,
prior to coupling the double-stranded oligo to the
beads. DNA prepared in this manner bound NCL in
equal or greater quantities than DNA that had been
annealed at an equimolar ratio of the biotinylated to
non-biotinylated strands (Fig. 2A, left panel; Fig. 2B).
Furthermore, NCL did not bind specifically to either
of the two single strands when they were biotiny-
lated, coupled to streptavidin beads, and tested
separately by NAPSTER (not shown). Therefore NCL
binds to a double-stranded AP-1 DNA sequence.
Nucleolin Binds to the AP-1 Site in Gel Shift Assays
In addition to NAPSTER we performed gel shift
assays with NE from human MCF-7 breast cancer
cells (Fig. 2C). The AP-1 shift is competed by
preincubation with wt but not mut unlabeled AP-1
oligo. Preincubation of NE with ac-Jun causes a
supershifted band to appear. Preincubation of NE
with aNCL significantly blocks the AP-1 shift, where-
as non-immune IgG does not. Preincubation of NE
with a second independent antibody against NCL
also decreases the signal intensity (not shown). These
data demonstrate that NCL binding to the AP-1 site is
detectable by both NAPSTER and gel shift methods.
Nucleolin Represses Transactivation of
AP-1-Dependent Gene Expression
To examine the functional consequences of
nucleolin/AP-1 sequence interaction, we generated
AP-1 luciferase reporter constructs that harbor AP-1
DNA binding sequences identical to those used in
NAPSTER assays [25]. Constructs were generated by
subcloning a wt AP-1 site or an AP-1 site with
inactivating mutations in it (mut). HeLa cells were
transiently co-transfected with wt or mut minimal
Figure 1. NAPSTER purification of Coomassie-stained p97 protein
specifically bound to the AP-1 DNA sequence. p97 protein from
NAPSTER samples I, II, and III were each purified and subjected to
Coomassie staining from 600 mg of HT29 NE starting material as
described in Materials and Methods. I, no competitor oligo; II,
preincubation with wt AP-1 oligo; III, preincubation with mut AP-1
oligo. NE, 30 mg of nuclear extract, directly loaded.
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AP-1 luciferase reporter constructs, a NCL over-
expression construct, and a constitutive b-gal expres-
sion construct. Cells were then treated with TPA or
with dimethyl sulfoxide (DMSO) control solvent
and analyzed for luciferase activity. TPA enhances by
3.5-fold AP-1 transactivation of the wt AP-1 reporter
construct (Fig. 3A), but has no effect upon the
mut AP-1 reporter construct. Overexpressed NCL
represses TPA-induced AP-1 transactivation of the wt
AP-1 reporter by 72%. NCL also mildy represses
transactivation even in the absence of TPA, by
23% (not shown). NCL does not repress transactiva-
tion of the mutant AP-1 reporter in TPA-treated or
untreated cells, demonstrating that NCL repression
is dependent upon the AP-1 DNA sequence. Lucifer-
ase activity of the mutated minimal AP-1 reporter
construct is sufficiently high that repression
would have been readily detectable had it occurred
(700–2000 U of raw luciferase activity vs. back-
ground levels of 50–80 U). Expression of transfected
NCL was confirmed by immunoblotting with aHA-
tag antibodies (for detection of HA-tagged NCL; Fig.
3B), and with aNCL (Fig. 3C). Equal loading of
protein from lysates of transfected cells was verified
by Western immunoblotting with anti GAPDH anti-
body (not shown). Total intracellular levels of
NCL protein, detected by immunoblotting with
aNCL, increase at least 1.7-fold as a consequence of
NCL overexpression. This moderate increase is
expected in light of the fact that NCL is a highly
expressed endogenous protein. Overexpressed HA-
NCL in Figure 3C appears as a band with slightly
less mobility than the endogenous protein in
SDS–PAGE, most likely because of the HA-tag
present on the overexpressed molecule.
As for TPA-induced AP-1 transactivation, nucleo-
lin represses transactivation induced by overex-
pressed AP-1 components. Overexpressed human
c-fos from pcDNAc-fos, a CMV c-fos overexpression
construct, causes 2.5-fold induction of transactiva-
tion of the wt AP-1 reporter, but has no effect on
the mutated AP-1 reporter (Fig. 4A). NCL causes
73% repression of c-Fos mediated transactivation of
the wt AP-1 reporter. Overexpression of HA-NCL and
c-Fos proteins expressed by the CMV NCL and CMV
c-fos overexpression constructs were verified by
immunoblotting (Fig. 4B and C). NCL overexpres-
sion does not downregulate expression of endo-
genously expressed c-Fos protein, nor does it
downregulate protein expression from the CMV
promoter (not shown). Equal loading of protein
from lysates of transfected cells was verified by
Western immunoblotting with anti GAPDH anti-
body (not shown). NCL also represses transactivation
of a wt minimal AP-1 reporter construct induced by a
transfected junD overexpression construct, by 78%
(not shown).
Several independent measures of cell viability
after transfection of NCL were used to assess gene
Figure 2. Nucleolin binds in vitro to the AP-1 site. (A) p97 is nucleolin
by immunoblotting analyses of nuclear proteins bound to AP-1 DNA in
NAPSTER. NASPTER was performed with HT29 NE using the minimal
GALV AP-1 sequence. Immunoblotting of samples I, II, and III, as defined
in the legend of Figure 1 was performed with antibodies against the
antigens indicated above each panel. Left panel, aNCL (from Santa Cruz
Biotechnologies); middle panel, aJunD; right panel, aTopoisomerase I.
Assays were performed with 300 mg of input NE protein for each of
samples I, II, and III for samples immunoblotted with aNCL, and aTopoI,
and with 30mg for aJunD. (B) NCL from human HeLa cervical carcinoma
cells binds AP-1 DNA in NAPSTER. HT29 and HeLa NE samples containing
300 mg of protein were subjected to NAPSTER analyses for each of
samples I, II, and III, followed by Laemmli SDS–PAGE and immunoblotting
with aNCL (top row), or aJunD (bottom row). ‘‘NE,’’ 30 mg of directly
loaded HT29 or HeLa NE. AP-1 streptavidin beads used in this experiment
were prepared using AP-1 DNA that had been annealed using a 5:1 ratio
of the unbiotinylated strand to the biotinylated strand. (C) Nucleolin binds
the AP-1 site in gel shift analyses. Left panel: ‘‘-’’, no competitor oligo;
‘‘wt,’’ wild-type AP-1 competitor oligo; ‘‘mut,’’ mutated competitor AP-1
oligo (same mutations as those used for NAPSTER in Figures 1 and 2).
‘‘ac-Jun,’’ 1 mg ac-Jun preincubated with MCF-7 NE. pep, no peptide
antigen competitor preincubation; ‘‘þpep,’’ c-Jun peptide competitor
antigen preincubated with ac-Jun prior to gel shift assay as described
[29]. Arrow indicates position of c-Jun supershift. ‘‘IgG,’’ 2 mg of non-
immune IgG (Upstate Cell Signaling Solutions, Lake Placid, NY)
preincubated with MCF-7 NE prior to addition of labeled probe. Right
panel, ‘‘IgG,’’ 5 mg of non-immune IgG. Triangle denotes increasing
concentrations of anti NCL (‘‘aNCL’’) antibody (Active Motif, Inc.)
preincubated with MCF-7 NE. Left bracket: 2 mg aNCL; right bracket:
5 mg aNCL. Antibody preincubations were performed at RT for 60 min.
Left and right panels were two autoradiograms with the same exposure
time from the same experiment.
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toxicity as a possible mechanism of transrepression.
Counting of cells in a hemocytometer after transfec-
tion with NCL, and immunoblotting of equal
volumes of cell extracts with aGAPDH antibodies,
indicate little or no change in cell number as a
function of expression of the introduced genes (not
shown). Trypan blue exclusion assays also demon-
strated 97% viability of TPA-treated cells after
transfection of NCL, compared to 98% viability of
TPA-treated cells transfected with pcDNA3.1(þ)
control vector. Therefore AP-1 transrepression does
not occur through a non-specific toxic mechanism.
Figure 3. NCL represses transactivation of a minimal AP-1 reporter construct induced by TPA in HeLa cells. (A)
NCL represses AP-1-dependent gene transactivation. HeLa cells (2 105) were transiently co-transfected with 1 mg
of pNtag4 NCL overexpression construct or pcDNA3.1 (þ) vector control plasmid, with 2 mg of wild-type (3XwtAP-
1-luc) or mutant (3XmutAP-1-luc) GALV AP-1 luciferase reporter constructs, and with 0.6 mg pSVbgal b-
galactosidase (b-gal) expression construct. Transfection of pcDNA3.1(þ) control vector or of pNTag4 are indicated
in the NCL row under the bar graphs with ‘‘’’ and ‘‘þ’’, respectively. Transfectants were treated with TPA or
DMSO 4 h after transfection and were harvested 24 h later (‘‘þ’’ or ‘‘’’ respectively in TPA row below bar graphs).
Cell lysates from independently tranfected duplicate samples were generated and assayed for luciferase and b-gal
activity as described [25]. Data were normalized to b-gal expression. Error bars represent standard error of the
mean (SEM) of 14 independent experiments for wt and 7 independent experiments for mut transfectants, each
performed in duplicate. Statistical significance of differences in relative luciferase activity between wt 3XAP-1
luciferase reporter transfectants with or without TPA or nucleolin were assessed using the statistical test for analysis
of variance (ANOVA test, in which the minimum significance level was set at P value of 0.05). Calculated values for
TPA-treated wt 3XAP-1 transfectants were compared to corresponding samples within the test group (e.g.,
compared to wt 3XAP-1 transfected, TPA-untreated; wt 3XAP-1 transfected, TPA-treatedþNCL; mut 3XAP-1
transfected, TPA-treated), and were significant to P<0.001. Percentage repression was calculated according to the
formula:
100 ðActivity of wt reporter in TPA-treated cellsÞ  ðActivity of wt reporter plasmid in TPA-treated cells with pNtaq4ÞðActivity of wt reporter in TPA-treated cellsÞ  ðActivity of wt reporter plasmid in TPA-treated cellsÞ
where the values are all in units of relative activity, and where the relative activity of wt reporter in TPA-untreated,
pcDNA3.1(þ) transfected cells is defined as 1.0. (B) NCL overexpression in transient transfectants. Overexpression
of NCL was confirmed in transient pNtag4 transfectants versus pcDNA3.1(þ) control transfectants by Western
immunoblotting of 10 ml of lysate from each transfectant sample with anti HA-tag antibody. The identities of
samples numbered 1 through 6 correspond to the identities of the labeled bar graphs in (A), from left to right. (C)
NCL overexpression increases levels of total nucleolin protein. Cells transfected with 1 mg pNtag4 or with pcDNA
vector control were harvested, whole cell lysates were generated, and 10 mg of total protein were immunoblotted
with aNCL antibody.
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Collectively, these data demonstrate that NCL
specifically represses transactivation of AP1-depen-
dent gene expression of a minimal AP-1 reporter
construct.
Nucleolin Binds to the MMP-13 AP-1 Target Gene
Promoter In Vitro and In Vivo
MMP-13 is an endogenous AP-1 target gene that
encodes an ECM degrading endopeptidase with
important roles in tumor invasion and tissue remo-
deling [14,33]. The MMP-13 promoter contains an
AP-1 binding site [34]). As described above, NCL from
HeLa nuclear extracts binds in vitro to a minimal AP-
1 site. NCL is readily detected in the nucleoplasm of
HeLa cells, and overexpression of NCL does not alter
the levels of expression or the subcellular localiza-
tion of any of the seven AP-1 subunits (data not
shown). It also does not alter the abundance of post-
translationally modified forms of the AP-1 protein
subunits, such as phosphorylated c-Jun protein (not
shown). Based on these collective data we hypothe-
sized that NCL binds the MMP-13 AP-1 target gene
promoter sequence and regulates transactivation in a
manner that depends on the AP-1 site.
To determine whether NCL interacts with the
MMP-13 sequence in vitro and in vivo, we performed
NAPSTER and ChIP analyses with DNA sequences
from the human MMP-13 promoter. NAPSTER was
performed with an oligo coupled to streptavidin
beads, derived from a human MMP-13 promoter
sequence containing the AP-1 site. NCL binds to the
MMP-13 sequence, and mutational inactivation of
the AP-1 site blocks its binding to the sequence
(Fig. 5A, upper panel). JunD also binds specifically to
the AP-1 site in the MMP-13 sequence (Fig. 5A, lower
panel).
For ChIP analyses, PCR primers were designed that
amplified a region of the MMP-13 promoter that
contains the AP-1 site. PCR primers were designed
that flanked the AP-1 site within 64 bp upstream and
78 bp downstream of the AP-1 site (Table 2). A PCR
product of the expected size (142 bp) is reproducibly
observed using chromatin immunoselected with
aNCL antibodies. This signal is of significantly
greater intensity than that which is observed when
chromatin is immunoselected with control non-
immune IgG (Fig. 5B). Similar results were observed
in five independent experiments using three inde-
pendent chromatin preparations. Immunoselection
with a second, independently derived antibody
against NCL also yields a 142 bp PCR signal that is of
greater intensity than the signal that is obtained with
non-immune IgG (not shown). Immunoselections
Figure 4. NCL represses transactivation induced by c-fos transfected into HeLa cells. (A) Cells were co-
transfected with 10 ng of pcDNAc-fos, plus 1 mg of pNtag4 nucleolin overexpression construct or pcDNA3.1 (þ)
vector control plasmid, with wild-type or mutant 3XAP-1-luc AP-1 reporter constructs, and with 0.6 mg of pSVbgal
overexpression construct. All data were normalized to b-gal expression. c-fos row: ‘‘,’’ no c-fos; ‘‘þ,’’ 10 ng c-fos.
NCL row: 1 mg pcDNA 3.1(þ) indicated by ‘‘,’’1 mg pNTag4 indicated by ‘‘þ.’’ Each value represents the
mean SEM of five independent experiments, each performed in duplicate and is expressed relative to the control
3XwtAP-1-luc activity in the absence of c-fos and without any TPA treatment. Calculated values for fos-transfected
wt 3XAP-1 transfectants were compared to corresponding samples within the test group (e.g., wt 3XAP-1
transfected, fos-untransfected; wt 3XAP-1 transfected fos-transfectedþNCL; mut 3XAP-1 transfected fos-
transfected), and were significant to P< 0.01, using the ANOVA test. (B) Confirmation of NCL overexpression by
immunoblotting analyses with anti HA-tag antibodies. The identities of samples numbered 1 through six
correspond to the identities of the labeled bar graphs in (A), from left to right. (C) Transfection of c-fos increases
total intracellular levels of c-Fos protein. Cells transfected with pcDNAc-Fos or with pcDNA3.1(þ) vector control
were harvested following 24 h treatment with 100 ng/ml TPA, whole cell lysates were generated, and 10 mg of total
protein were immunoblotted with anti c-Fos antibody.
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performed with aJunD yield significantly more PCR
product than control IgG, showing that JunD also
binds to the MMP-13 promoter sequence. The signal
intensity observed for samples incubated with beads
in the absence of non-immune IgG is equal to that of
samples selected with beads in the presence of non-
immune IgG, indicating that the PCR signal detected
in IgG samples is attributable to background binding
to beads. These data show that NCL binds to the
MMP-13 promoter in the vicinity of the AP-1 site. In
vitro NAPSTER studies were predictive of in vivo
ChIP assay results.
A number of control studies were performed to
validate these results. PCR signals for ChIP selections
performed with aNCL and aJunD increase linearly as
a function of the increased PCR cycle number, and as
a function of the quantity of input chromatin (not
shown), indicating that observed differences in
signal intensity occur within the linear range of
detection. NCL is detectable by Western immuno-
blotting of samples immunoprecipitated with aNCL
antibody under ChIP conditions (not shown).
Immunoselection with aNCL yields more ChIP PCR
product than nonimmune IgG using PCR primers
Figure 5. NCL binds to the MMP-13 promoter sequence in vitro and in vivo. (A) NCL and JunD bind to the MMP-
13 promoter sequence in a manner that depends upon the AP-1 sequence. NAPSTER was performed with 150 mg
NE from TPA-treated HeLa cells and with 10 mg of MMP-13 oligo on DNA affinity beads. Preincubations were
performed with 25 mg of unconjugated wt (sample II) or mut (sample III) MMP-13 oligo. aNCL, upper panel; aJunD,
lower panel. In addition to the two JunD bands that bind the site, a band that migrates more slowly binds non-
specifically, since it is present in all three samples. (B) NCL and JunD bind to the MMP-13 promoter in chromatin
immunoprecipitation assays. Immunoselections were performed with aNCL, aJunD, and nonimmune IgG,
respectively. ‘‘,’’ PCR amplification performed with H2O only, without antibodies or IgG (control for PCR
background contamination); ‘‘input,’’ 5 ng of unselected chromatin subjected to PCR with primers flanking the AP-
1 site within 64 bp upstream and 78 bp downstream of the AP-1 site within the MMP-13 promoter. M, markers;
bp, base pairs. (C) Nucleolin binds to the matrix attachment region sequence. All samples were PCR amplified with
primers that flank within 62 bp upstream and 60 bp downstream of the NCL binding site within the human matrix
attachment region (MAR). (D) Nucleolin does not bind to the GAPDH promoter region containing a TFIIB
transcription factor binding site. aTFIIB, imunoselection with antibody against transcription factor TFIIB. All samples
were PCR amplified with primers that flank within 120 bp upstream and 46 bp downstream of the TFIIB binding site
(TATA box) within the human GAPDH promoter.
Table 2. PCR Primers Used for Chromatin Immunoprecipitation Analyses
Primer set Primer sequence Annealing temp.
PCR product
size
MMP-13 For 50-CCACGTAAGCATGTTTACCTTCAAGTGAC-30 638C 142 bp
Rev 50-GATGCATCTTGAATGGTGATGCCTGG-30
GAPDH For 50-TACTAGCGGTTTTACGGGCG -30 598C 166 bp
Rev 50-TCGAACAGGAGGAGCAGAGAGCGA-30
MAR For 50-GGCATTTTACAATGGGAAAATGATG-30 588C 122 bp
Rev 50-CACTGGAATTTTTTTGTGTGTATGG-30
For, forward primers; rev, reverse primers.
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that amplify a region of the matrix attachment
region (MAR), thus showing binding of NCL to a
previously characterized NCL DNA binding
sequence (Fig. 5C). Enhanced PCR signal intensity
is not observed in aNCL immunoselections com-
pared to control IgG selections employing primers
within the MMP-13 coding region 2.6 kb down-
stream of the of the promoter sequence, indicating
that NCL does not bind to this region (not shown).
NCL does not bind to sequences within the GAPDH
gene promoter, which has no AP-1 sites, since the
intensity of the PCR signal detected for aNCL
immunoselected samples amplified with primers
for the GAPDH gene is not greater than that which
is detected for samples immunoselected with non-
immune IgG (Fig. 5D). However, binding of the TFIIB
transcription factor to its binding site within the
GAPDH amplified sequence is detected. Taken
together, these data show that NCL binds in vivo to
the MMP-13 promoter, in the vicinity of the AP-1
site.
Overexpression of Nucleolin Represses Transactivation
of the MMP-13 Promoter
TPA induces transactivation of a human MMP-13
luciferase promoter reporter construct containing a
single AP-1 site by 2.8-fold (Fig. 6). Overexpressed
NCL represses 93% of TPA-induced transactivation
of the MMP-13 promoter. Mutational inactivation of
the AP-1 site abrogates TPA induction of MMP-13
transactivation, and it abrogates NCL repression.
Luciferase activity of the mutated MMP-13 construct
is sufficiently high that repression would have been
readily detectable had it occurred (300–1500 U of
raw luciferase activity for the mutated constructs, vs.
50–80 U of background activity).
DISCUSSION
DNA binding of NCL has been shown to regulate
gene expression at several transcriptional promoter
motifs [16,35–38]. These include the bone-specific
osteocalcin promoter element OC I, the human
papilloma virus-18 enhancer, and the B sequence
motif within the alpha-1 acid glycoprotein promoter
[35,36,38]. NCL has been shown to activate tran-
scription from Em, Fp, HPV-18, and c-myc promoter
and enhancer sequences, and represses transcription
from the alpha-1 acid glycoprotein promoter
[35,37,38]. Nucleolin is required for polymerase I
transcription of rDNA, and it functions as a histone
chaperone for remodeling of nucleosomes in chro-
matin [22,39]. This is the first report of NCL binding
to an AP-1 site and controlling AP1-dependent gene
expression. Whereas NCL has been shown to post-
transcriptionally upregulate matrix metalloprotei-
nase-9 (MMP-9), this is the first report of NCL
transcriptional regulation of a matrix metalloprotei-
nase.
A number of bZIP proteins of the AP-1 superfamily
bind specifically to the minimal seven base pair AP-1
consensus sequence, and regulate transactivation
[40–48]. Non-bZIP transcription regulatory proteins
have been found to repress AP1-dependent transac-
tivation [38,49–58], (see Reference [59] for review).
Binding of non-bZIP proteins to the AP-1 site has not
been demonstrated, and in many instances has been
ruled out. Recently we reported that Y-box binding
protein-1 (YB-1) binds to the AP-1 site and also
represses AP-1 transactivation [25]. NCL and YB-1
have been found together in several large multi-
component ribonucleoprotein complexes, and
nucleolin is detected in complexes with YB-1 in
GST pulldown assays [60–62]. Future experiments
will determine whether YB-1 and NCL form a ternary
complex at the AP-1 site. To our knowledge, YB-1 and
NCL are the first non-bZIP AP-1 DNA binding
proteins outside the AP-1 superfamily that bind the
AP-1 site and repress AP-1 transactivation.
The original purifications of AP-1 proteins were
performed in groundbreaking studies in 1987 using
purification schemes employing AP-1 DNA affinity
chromatography [11,12]. Whereas AP-1 was the
dominant species in these purifications, NCL binds
the AP-1 DNA in greater abundance than AP-1
proteins in NAPSTER purifications, since NCL is
visible by Coomassie staining, whereas AP-1 species
are only visible upon Western Immunoblotting
Figure 6. NCL represses MMP-13 transactivation. (A) NCL
represses MMP-13 transactivation via the AP-1 site. HeLa cells were
transfected with 1 mg of wt or mut human MMP-13 promoter
luciferase reporter constructs (5223 bp), along with 1 mg of pNtag4
NCL overexpression construct or pcDNA3.1(þ) vector control
construct (for ‘‘’’ NCL samples). Samples were treated with 100
ng/ml TPA or with DMSO control solvent for 24 h prior to harvest.
Each value represents the mean SEM of seven independent
experiments, each performed in duplicate and is expressed relative
to the control wt MMP-13 luciferase activity in the absence of NCL
and without any TPA treatment. Calculated values for TPA-treated
wt MMP-13 transfectants were compared to corresponding samples
within the test group (e.g., wt MMP-13 transfected, TPA-untreated;
wt MMP-13 transfected, TPA-treatedþNCL; mut MMP-13 trans-
fected, TPA-treated), and were significant to P< 0.001 using the
ANOVA test.
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analyses (Fig. 1 and data not shown). One of the
original AP-1 purification schemes used HeLa cell
nuclear extracts [11], which have readily detectable
NCL AP-1 DNA binding activity in our hands. It is
possible that NCL was isolated in the original work,
in which a minor silver-stained species was found at
116 kDa from HeLa cells that co-purified with AP-1
[11]. p116 was not pursued or identified. Or it may
be that p116 is poly ADP (ribose) polymerase, a
common contaminant in DNA affinity purified
protein fractions [63]. It is also possible that NCL
was lost in the original purifications. Whereas our
purification protocol consists of only two steps, the
original purifications consisted of multiple steps
performed before the AP-1 DNA affinity chromato-
graphy step, including ammonium sulfate precipita-
tion, molecular sieve chromatography, heparin
affinity chromatography, and stepwise KCl elution
after DNA affinity chromatography. These addi-
tional steps may have removed NCL from these
preparations.
Binding of NCL to the AP-1 DNA sequence is
independent of the binding of AP-1 proteins to the
AP-1 site, since immunodepletion of AP-1 with anti
PAN Jun/Fos antibodies has no effect upon the
binding of NCL to the AP-1 DNA sequence [26].
Furthermore, since we see NCL binding in NAPSTER
in excess relative to AP-1 protein binding, binding of
NCL would necessarily occur without AP-1 proteins.
The possibility that NCL binds the AP-1 site along
with other proteins, such as YB-1, has not been ruled
out, and is under investigation.
MMP-13 belongs to the large family of MMP
enzymes, and has broad substrate specificity for
ECM macromolecules [14,33]. MMP-13 expression
in healthy tissues is restricted to circumstances in
which rapid remodeling of ECM within target tissue
is required [64], particularly in development and
tissue remodeling in bone and cartilage [65]. MMP-
13 is also upregulated in capillary tube formation
in vitro, and may play an important role in
endothelial cell invasion during angiogenesis
[66,67]. Elevated MMP-13 activity outside of these
venues is pathological. It causes connective tissue
destruction in arthritis [65]. It is observed in many
cancerous tumors, and is associated with invasive,
metastatic behavior and poor disease prognosis, and
it also mediates mammary carcinogenesis [14,33,68].
Overexpression of MMP-13 enhances invasiveness,
and targeted inhibition of MMP-13 inhibits invasion
and tumor growth [27,64]. Transgenic mice over-
expressing jun or fos AP-1 subunits or with targeted
knockout of jun or fos AP-1 subunits have demon-
strated that AP-1 mediates invasion and all of the
above biological processes [2,14,33,67–70]. Trans-
genic overexpression of jun and fos upregulates
expression of MMPs and targeted disruption down-
regulates expression of MMPs. C-fos overexpression
in transgenic mice induces MMP-13 expression and
causes osteosarcomas, whereas c-fos knockout mice
show significantly reduced MMP-13 induction
[71,72]. Ablation of the junB gene in endothelial
cells blocks transactivation of the MMP-13 promoter
and inhibits capillary tube morphogenesis [67].
These and other studies demonstrate that MMPs
including MMP-13 are key downstream AP-1 target
genes that implement matrix degradation in inva-
sion and a range of other physiological and patho-
logical processes.
Induced expression of MMP-13 in cells requires
binding of AP-1 to its binding sequences within the
MMP-13 promoter [69,70]. Since AP-1 plays impor-
tant roles in mediating tumor invasion, tissue
remodeling, wound healing, angiogenesis, arthritis,
and other processes, and since NCL represses trans-
activation of the AP-1 sequence, it is logical to
hypothesize that NCL may mediate one or more of
these processes. Future experiments will determine
whether NCL mediates some of these processes by
binding and downregulating AP-1 transcriptional
activity within the MMP-13 promoter.
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